Literature DB >> 8473885

Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives.

P T Francis1, N R Sims, A W Procter, D M Bowen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8473885     DOI： 10.1111/j.1471-4159.1993.tb13381.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN： 0022-3042            Impact factor:   5.372


× No keyword cloud information.
  39 in total

1.  Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe.

Authors:  M Carli; C Balducci; R Samanin
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability.

Authors:  Giovanni Pennisi; Raffaele Ferri; Giuseppe Lanza; Mariagiovanna Cantone; Manuela Pennisi; Valentina Puglisi; Giulia Malaguarnera; Rita Bella
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

4.  beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects.

Authors:  A W Procter; P T Francis; C Holmes; M T Webster; M Qume; G C Stratmann; R Doshi; D M Mann; P J Harrison; R C Pearson
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

5.  Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

Authors:  Angela M Floden; Shanshan Li; Colin K Combs
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

6.  Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors.

Authors:  R K Lee; R J Wurtman; A J Cox; R M Nitsch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 7.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

8.  Imaging of glutamate neurotransmitter alterations in Alzheimer's disease.

Authors:  Mohammad Haris; Kavindra Nath; Kejia Cai; Anup Singh; Rachelle Crescenzi; Feliks Kogan; Gaurav Verma; Sanjana Reddy; Hari Hariharan; Elias R Melhem; Ravinder Reddy
Journal:  NMR Biomed       Date:  2012-10-09       Impact factor: 4.044

9.  Combined treatment with a 5HT1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior.

Authors:  M Riekkinen; J Sirviö; T Toivanen; P Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 10.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.